Searched for
NORTH AMERICA GENERICS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- India's biggest trade bet comes with six red flagsIndia may be adding more trade partners, but its latest FTA report card comes with several red marks. A new study by the Global Trade Resea...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIf the US-Iran ceasefire holds, the markets may see some recovery. The movement of crude oil prices and its impact on the markets supports ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the latest news flow from the Gulf region, the probability is high that we might once again see the bulls attempting a comeback. As u...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announcedDr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter ...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Outlook login not working? What caused Microsoft Outlook outage today — and was it Hacked?Is Outlook Down Right Now? Outlook login not working? What caused the Microsoft Outlook outage today — and was it hacked? Microsoft stayed ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsOver the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...
- Pharma exports fall to five-year low in March amid West Asia crisisIndia's pharma exports saw a sharp 23.17% fall in March. The West Asia war disrupted shipping routes and air transit hubs. This led to incr...
- Dr Reddy's launches authorised generic of Vasostrict injection“We are pleased to provide this important authorized generic product to patients, especially in these difficult times of COVID-19,” says Ma...
- Dr Reddy's launches generic epilepsy drug in US market"We are pleased that this product has been designated as a Competitive Generic Therapy (CGT) by the FDA," Dr Reddy's Laboratories North Ame...
- Dr Reddy's launches generic arthritis drug in US market"The launch of product is an important addition to our pain/analgesics portfolio of over-the-counter (OTC) products, and represents our con...
- Dr Reddy's picks Alok Sonig to lead North America generics businessIn a top level reshuffle, drug major Dr Reddy's Laboratories appointed Alok Sonig as Executive Vice President & Head for its generics busin...
- Dr Reddy's expects North American biz to drive growth this FYDr Reddy's Laboratories expects generics business in North America to be its main growth driver this fiscal.
Load More
